PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7989400

Steroids in multiple sclerosis.

T D Griffiths·P K Newman
View original source ↗Export metadata ↓

Abstract

Steroids are widely used in treating the relapse of multiple sclerosis. There is no place for long term steroid therapy of this disease. Current practice is a short course of high dose methylprednisolone which can be repeated after an interval, has proven safety and objectively accelerates recovery.

Explore related subjects

Cost-Benefit AnalysisDrug Administration ScheduleDrug Delivery SystemsDrug EvaluationHumansMethylprednisoloneMultiple SclerosisRecurrenceClinical TrialComparative StudyJournal ArticleMulticenter StudyRandomized Controlled TrialReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T D Griffiths, P K Newman. 1994. Steroids in multiple sclerosis.. https://doi.org/10.1111/j.1365-2710.1994.tb00677.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Evidence rather than costs must guide use of the implantable cardioverter defibrillator.

Randomized controlled trials have shown superior survival rates with implantable cardioverter defibrillators (ICDs) compared with antiarrhythmic drugs in survivors of cardiac arrest and life-threatening ventricular tachyarrhythmias, as well as in high-risk patients with ischemic heart disease and inducible ventricular tachycardia (VT). Current defibrillators are small and implanted with techniques similar to standard pacemakers. They provide high-energy shocks for ventricular fibrillation (VF) and rapid VT, antitachycardia pacing for monomorphic VT, and antibradycardia pacing. Limited evidence suggests that ICD therapy is cost-effective when compared with other widely accepted treatments. The use of ICDs is likely to continue to expand in the future. Ongoing clinical trials will define further prophylactic indications of the ICD and clarify its cost-effectiveness ratio in different clinical settings.

Cost-Benefit Analysis↗